Prollenium

Where Prollenium fits

Prollenium is the manufacturer med spas turn to when they want HA filler economics to work harder. Founded in 2002 and headquartered in Aurora, Ontario, the privately held company is North America's only vertically integrated hyaluronic-acid filler maker: it develops, manufactures, and ships the Revanesse line — Versa, Versa+, and Lips+ — from its own facilities. That vertical integration is more than a marketing line. It gives Prollenium supply-chain control, batch consistency, and the cost structure to price below Juvéderm and Restylane while staying FDA-approved and North-American-made.

In practice, Revanesse plays one of two roles on a med spa menu: the workhorse filler for volume-driven practices protecting margin, or the value tier offered alongside a premium franchise for price-sensitive patients.

What stands out

The value equation is the core of the story. Per-syringe acquisition costs are consistently below the legacy HA franchises, which either widens margin at your current patient price or lets you compete at a lower retail point without touching profitability. For practices doing meaningful filler volume, the annual difference is real money.

Clinically, Versa's low-swell reputation gives injectors a concrete chair-side talking point, particularly for lips, where next-day presentability matters to patients. Versa+ adds lidocaine for comfort, and Lips+ gives the line a dedicated lip indication.

The direct account model also earns marks. Rather than routing everything through distributors, Prollenium runs direct US practice accounts backed by field reps, and practices generally describe the reps as accessible and less bureaucratic than big-pharma counterparts. Reordering is straightforward, and promotions are managed at the rep level, where smaller accounts still get attention.

Where it falls short

Prollenium is an HA specialist, full stop. There is no neurotoxin, no biostimulator, no skincare, and no device business, so it cannot be your only injectables relationship — most practices run Revanesse alongside a toxin vendor and often a second filler franchise. The SKU range is also narrower than Juvéderm's or Restylane's: for specialized indications like deep structural work or hands, you may still reach for a competitor's product.

Consumer brand pull is limited. Patients walk in asking for Juvéderm; almost nobody asks for Revanesse by name, so the switch depends on injector confidence and price framing rather than demand-side marketing. And as everywhere in this category, wholesale pricing is rep-negotiated rather than published, so comparison shopping requires getting quotes on the table.

Who should choose it

Choose Prollenium if filler is a volume business for you and margin discipline matters — Revanesse is arguably the best cost-per-syringe story among FDA-approved HA lines, with the added comfort of North American manufacturing. It is an easy addition as a value tier even for practices committed to a premium franchise, and the direct-rep model suits independent med spas that want a responsive human relationship rather than a portal queue. Practices that need one vendor to consolidate toxin, filler, and skincare purchasing, or that rely on patient-driven brand demand, should treat Revanesse as a complement to — not a replacement for — the incumbent franchises.